China Medical System Holdings (HKSE:00867) GF Score : 96/100 (As of Jun. 09, 2024)

View and export this data going back to 2010. Start your Free Trial

What is China Medical System Holdings GF Score?

China Medical System Holdings has the GF Score of 96, which implies that the company might have Highest outperformance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 10/10
2. Profitability Rank : 10/10
3. Growth Rank : 10/10
4. GF Value Rank : 9/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes China Medical System Holdings might have Highest outperformance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of China Medical System Holdings's GF Score

For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Medical System Holdings's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where China Medical System Holdings's GF Score falls into.

China Medical System Holdings (HKSE:00867) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

China Medical System Holdings GF Score Related Terms

Thank you for viewing the detailed overview of China Medical System Holdings's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

China Medical System Holdings (HKSE:00867) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Medical System Holdings Ltd (HKSE:00867) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

2M7C:Germany

Address

510 King’s Road, Unit 2106, 21st Floor, North Point, Island Place Tower, Hong Kong, HKG

Website

http://www.cms.net.cn

China Medical System Holdings Ltd is active in the healthcare segment. It is one of the leading China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil; Salofalk; Combizym; Ganfule Capsules; Xidakang; Hirudoid; and others. Geographically, it derives revenue from China.

Executives

Treasure Sea Limited	2101 Beneficial owner
Lam Kong	2201 Interest of corporation controlled by you

China Medical System Holdings (HKSE:00867) Headlines

No Headlines